Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Maze Therapeutics, Inc. (MAZE) had Return on Tangible Equity of -11.19% for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-47.97M |
|
-- |
|
-- |
|
$51.52M |
|
$-51.52M |
|
$3.55M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-47.97M |
|
$-51.52M |
|
$-50.97M |
|
60.87M |
|
60.87M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$400.10M |
|
$4.35M |
|
$111.45M |
|
$511.56M |
|
$28.30M |
|
$39.12M |
|
$54.71M |
|
$83.01M |
|
$428.55M |
|
$428.55M |
|
$428.55M |
|
56.45M |
|
| Cash Flow Statement Financials | |
$-87.01M |
|
$-153.64M |
|
$205.56M |
|
$190.34M |
|
$155.24M |
|
$-35.09M |
|
$24.84M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.14 |
|
-- |
|
-- |
|
0.08 |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-87.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.19% |
|
|
Return on Tangible Equity |
-11.19% |
-9.38% |
|
-10.26% |
|
$7.59 |
|
$-1.44 |
|
$-1.43 |
|